Cybin Inc., a biotechnology company based in Ontario, Canada, has filed a Form D Notice of Exempt Offering of Securities with the United States Securities and Exchange Commission (SEC) on April 19, 2024. The filing indicates a new notice with the date of the first sale being April 5, 2024. The offering is expected to last more than one year and includes options, warrants, or other rights to acquire another security, specifically stock options exercisable at CAD$0.56 per share vesting in eight quarterly tranches beginning June 30, 2024. The total offering amount is listed as $1,904,692 USD, with none sold at the time of the filing. Cybin Inc. has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act...Show More

Cybin Inc., a biotechnology company based in Ontario, Canada, has filed a Form D Notice of Exempt Offering of Securities with the United States Securities and Exchange Commission (SEC) on April 19, 2024. The filing indicates a new notice with the date of the first sale being April 5, 2024. The offering is expected to last more than one year and includes options, warrants, or other rights to acquire another security, specifically stock options exercisable at CAD$0.56 per share vesting in eight quarterly tranches beginning June 30, 2024. The total offering amount is listed as $1,904,692 USD, with none sold at the time of the filing. Cybin Inc. has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company has not made this offering in connection with a business combination transaction and has not paid any sales commissions or finder's fees. The proceeds from the offering are not intended to be used for payments to any executive officers, directors, or promoters as per the filing. The named executive officers and directors include Douglas Drysdale, George Tziras, Eric So, Gabriel Fahel, Paul Glavine, Greg Cavers, Aaron Bartlone, Theresa Firestone, Mark Lawson, Grant Froese, and Eric Hoskins.